Making the scientific case for testing CBD in treatment-resistant epilepsy
Pure CBD showed strong anticonvulsant properties in animal models and appeared well tolerated in humans, making it an ideal candidate for clinical trials in treatment-resistant epilepsy.
Quick Facts
What This Study Found
This editorial-style review from leading epilepsy researchers argued that pure CBD had accumulated sufficient preclinical evidence to justify systematic clinical investigation for treatment-resistant epilepsy. Basic research had demonstrated strong anticonvulsant effects in acute animal models, though data from chronic models was limited.
CBD appeared to be well tolerated in available human data, and importantly, it lacked the psychotropic effects of THC that limit tolerability. Previous human epilepsy studies had been small and methodologically limited, with inconclusive results. Recent anecdotal reports of high-CBD medical marijuana showed promise but lacked controlled conditions.
The authors called for systematic safety, pharmacokinetic, and drug interaction studies as a foundation for double-blind, placebo-controlled efficacy trials, particularly targeting Dravet and Lennox-Gastaut syndromes.
Key Numbers
No specific trial data were reported. The review cited strong preclinical anticonvulsant evidence and limited but promising human data. Target populations identified: Dravet syndrome and Lennox-Gastaut syndrome.
How They Did This
Expert review and commentary on the state of evidence for CBD in epilepsy, including preclinical data, available human evidence, and proposed clinical trial strategy.
Why This Research Matters
This paper, authored by researchers who would go on to lead the pivotal CBD epilepsy trials, laid the intellectual groundwork for the clinical development program that ultimately led to FDA approval of Epidiolex in 2018.
The Bigger Picture
This review appeared at a crucial moment in cannabinoid medicine. Public demand for CBD-based epilepsy treatments was growing rapidly, while scientific evidence remained limited. The authors bridged the gap between public enthusiasm and scientific rigor by outlining a systematic path to controlled clinical evidence.
What This Study Doesn't Tell Us
The anticonvulsant mechanisms of CBD were not fully understood. Human evidence was limited to small, methodologically weak studies and anecdotal reports. Drug interactions between CBD and existing antiepileptic medications were unknown.
Questions This Raises
- ?All questions raised by this paper were subsequently addressed by clinical trials: CBD was proven effective for Dravet and Lennox-Gastaut syndromes and received FDA approval in 2018.?
Trust & Context
- Key Stat:
- Strong preclinical anticonvulsant evidence supported systematic CBD clinical trials
- Evidence Grade:
- Expert review summarizing the evidence base and calling for rigorous clinical trials. The subsequent trials confirmed the premise.
- Study Age:
- Published in 2014, four years before FDA approval of CBD (Epidiolex) for epilepsy in 2018.
- Original Title:
- The case for assessing cannabidiol in epilepsy.
- Published In:
- Epilepsia, 55(6), 787-90 (2014)
- Authors:
- Cilio, Maria Roberta(5), Thiele, Elizabeth A(7), Devinsky, Orrin(9)
- Database ID:
- RTHC-00787
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Did CBD get approved for epilepsy?
Yes. This 2014 review called for the clinical trials that were subsequently conducted. Pure CBD (Epidiolex) received FDA approval in 2018 for Dravet syndrome and Lennox-Gastaut syndrome, two severe forms of treatment-resistant epilepsy.
How is CBD different from marijuana for epilepsy?
CBD is the non-psychoactive component of cannabis. Unlike THC, it does not produce a "high." This review argued that pure CBD, isolated from the rest of the cannabis plant, was the ideal candidate for rigorous epilepsy testing.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00787APA
Cilio, Maria Roberta; Thiele, Elizabeth A; Devinsky, Orrin. (2014). The case for assessing cannabidiol in epilepsy.. Epilepsia, 55(6), 787-90. https://doi.org/10.1111/epi.12635
MLA
Cilio, Maria Roberta, et al. "The case for assessing cannabidiol in epilepsy.." Epilepsia, 2014. https://doi.org/10.1111/epi.12635
RethinkTHC
RethinkTHC Research Database. "The case for assessing cannabidiol in epilepsy." RTHC-00787. Retrieved from https://rethinkthc.com/research/cilio-2014-the-case-for-assessing
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.